Calcium carbimide

	WikiDoc Resources for Calcium carbimide
Articles
Most recent articles on Calcium carbimide Most cited articles on Calcium carbimide Review articles on Calcium carbimide Articles on Calcium carbimide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Calcium carbimide Images of Calcium carbimide Photos of Calcium carbimide Podcasts & MP3s on Calcium carbimide Videos on Calcium carbimide
Evidence Based Medicine
Cochrane Collaboration on Calcium carbimide Bandolier on Calcium carbimide TRIP on Calcium carbimide
Clinical Trials
Ongoing Trials on Calcium carbimide at Clinical Trials.gov Trial results on Calcium carbimide Clinical Trials on Calcium carbimide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Calcium carbimide NICE Guidance on Calcium carbimide NHS PRODIGY Guidance FDA on Calcium carbimide CDC on Calcium carbimide
Books
Books on Calcium carbimide
News
Calcium carbimide in the news Be alerted to news on Calcium carbimide News trends on Calcium carbimide
Commentary
Blogs on Calcium carbimide
Definitions
Definitions of Calcium carbimide
Patient Resources / Community
Patient resources on Calcium carbimide Discussion groups on Calcium carbimide Patient Handouts on Calcium carbimide Directions to Hospitals Treating Calcium carbimide Risk calculators and risk factors for Calcium carbimide
Healthcare Provider Resources
Symptoms of Calcium carbimide Causes & Risk Factors for Calcium carbimide Diagnostic studies for Calcium carbimide Treatment of Calcium carbimide
Continuing Medical Education (CME)
CME Programs on Calcium carbimide
International
Calcium carbimide en Espanol Calcium carbimide en Francais
Business
Calcium carbimide in the Marketplace Patents on Calcium carbimide
Experimental / Informatics
List of terms related to Calcium carbimide

Calcium carbimide
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N07BB02 (WHO) ;
Identifiers
	IUPAC name calcium 2-hydroxypropane-1,2,3-tricarboxylate; methylcyanamide;
CAS Number	8013-88-5 ;
PubChem CID	6335910;
ChemSpider	21106422 ;
UNII	ZLR270912W;
ChEMBL	ChEMBL2106095 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C6H8O7.CH2N2.Ca
Molar mass	288.268 g/mol
3D model (JSmol)	Interactive image;
	SMILES [Ca+2].O=C([O-])CC(O)(CC(=O)O)C([O-])=O.N#CNC;
	InChI InChI=1S/C6H8O7.C2H4N2.Ca/c7-3(8)1-6(13,5(11)12)2-4(9)10;1-4-2-3;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);4H,1H3;/q;;+2/p-2 ; Key:ZZOBQLACMMNMCT-UHFFFAOYSA-L ;
(what is this?) (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Calcium carbimide, sold as the citrate salt under the trade name Temposil, is an alcohol sensitizing agent. Its effects are similar to the drug disulfiram (Antabuse) in that it interferes with the normal metabolism of alcohol by preventing the breakdown of the metabolic byproduct acetaldehyde. The result is that when alcohol is consumed by users of calcium carbimide, they experience severe reactions which include symptoms such as sweating, difficulty breathing, rapid heartbeat, rash, nausea and vomiting, and headache.

A recent 9-year study found that incorporation of supervised carbimide and the similar drug, disulfiram, into a comprehensive treatment program resulted in an abstinence rate of over 50%.^[1]

Temposil was developed by Drs. Ken Ferguson and Gordon Bell, who self-tested the drug on themselves.^[2] ^[3] ^[4] It was patented in 1955 by the Alcoholism Research Foundation of Ontario.^[5]

References

↑ Krampe H, Stawicki S, Wagner T; et al. (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism, clinical and experimental research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. ISSN 0145-6008. PMID 16433735.
↑ "Ogspi "PLO" 2005 Obituary". Ontario Genealogical Society.
↑ "Deaths - Canadian Medical Association Journal". Canadian Medical Association Journal.
↑ "Pioneer in Addiction Treatment Dr. Robert Gordon Bell Leaves Behind a Legacy of Hope and Healing" (PDF). Ontario Federation of Community Mental Health and Addiction Programs.
↑ "Booze: A Distilled History". Between The Lines. 2003.

Template:Drugs used in addictive disorders

[1] Krampe H, Stawicki S, Wagner T; et al. (January 2006). "Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome". Alcoholism, clinical and experimental research. 30 (1): 86–95. doi:10.1111/j.1530-0277.2006.00013.x. ISSN 0145-6008. PMID 16433735.

[2] "Ogspi "PLO" 2005 Obituary". Ontario Genealogical Society.

[3] "Deaths - Canadian Medical Association Journal". Canadian Medical Association Journal.

[4] "Pioneer in Addiction Treatment Dr. Robert Gordon Bell Leaves Behind a Legacy of Hope and Healing" (PDF). Ontario Federation of Community Mental Health and Addiction Programs.

[5] "Booze: A Distilled History". Between The Lines. 2003.

[1]

[2]

[3]

[4]

[5]

Calcium carbimide

Overview

See also

References

Navigation menu